Minerva Neurosciences has become one of the biggest stories in the biotech world this week as its stock price surged more than 130% following a major funding announcement. The clinical-stage biopharmaceutical company revealed that it secured up to $200 million in financing to advance its experimental schizophrenia treatment, a move that could reshape its financial trajectory and market standing.

The company’s shares on the Nasdaq traded under the symbol NERV and soared shortly after the news broke, closing with one of the highest single-day gains in its history. The announcement marks a crucial turning point for Minerva, which has faced years of volatility as it worked toward advancing roluperidone, its leading therapeutic candidate for treating the negative symptoms associated with schizophrenia.

A major financing deal to accelerate drug development

Minerva said the new funding comes through a securities purchase agreement with a group of institutional investors. The deal provides an initial $80 million in upfront capital, with the possibility of unlocking an additional $80 million if all Tranche A warrants are exercised. A further $40 million could be added through Tranche B warrants once the company reaches a specific milestone event.

This structured approach allows the company to maintain flexibility as it progresses through its clinical milestones. If all conditions are met, the total value of the financing package could reach $200 million, a level that significantly boosts the company’s ability to move forward with critical research and trial operations.

The financing comes just months after Minerva confirmed it had reached an agreement with the U.S. Food and Drug Administration on the design of a confirmatory Phase 3 trial for roluperidone. This study will focus on evaluating the treatment’s efficacy for negative symptoms in patients living with schizophrenia—a symptom group that remains one of the most challenging to treat effectively in modern psychiatry.

Strengthening leadership and scientific direction

As part of the financing deal, Minerva plans to restructure elements of its leadership team. Up to three new board members will be appointed, each with significant experience in schizophrenia-related clinical trials and psychiatric research. The addition of these directors is expected to provide specialized expertise and oversight for the company’s ongoing development programs.

The company will also establish a Scientific Advisory Board dedicated to guiding the upcoming confirmatory trial. This board will consist of experts in neuroscience, psychopharmacology, and clinical operations who will work closely with Minerva’s internal team to ensure that the trial design, execution, and analysis meet the rigorous standards required for regulatory approval.

What the funding means for Minerva’s future

The proceeds from this financing will primarily support three major areas: the execution of the confirmatory Phase 3 trial, the preparation for a New Drug Application resubmission to the FDA, and the groundwork for a potential commercial launch if the drug receives approval.

The Phase 3 study will evaluate a 64 mg dose of roluperidone in a randomized, double-blind, placebo-controlled setup. The primary endpoint will be the change in the PANSS Marder negative symptoms factor score at 12 weeks compared to placebo. This design aims to confirm the drug’s effectiveness in improving motivation, emotional expression, and other cognitive and social impairments that affect individuals with schizophrenia.

If successful, the trial could position Minerva as a leader in the treatment of negative symptoms—a domain where few existing medications provide significant relief. This would open a large, underserved market in the psychiatric drug landscape, potentially transforming Minerva into a key player in the neuropsychiatric treatment space.

Market reaction and investor outlook

Investors responded immediately to the news, with Minerva’s stock price soaring over 130% in premarket trading and sustaining strong gains through the day. The move reflected renewed confidence in the company’s long-term prospects, particularly as it prepares to restart late-stage clinical trials.

The private placement, led by Vivo Capital with participation from Janus Henderson and Federated Hermes Kaufmann Funds, is expected to close around October 23, 2025. This influx of institutional backing signals growing investor optimism about the potential for Minerva’s roluperidone to fill a critical unmet medical need.

With this latest development, Minerva appears poised to make substantial progress in its mission to address one of psychiatry’s most persistent challenges. Investors and industry observers alike will be watching closely as the confirmatory trial gets underway and the company moves one step closer to bringing its innovative treatment to patients who have long awaited new therapeutic options.

Source: Investing.com

Disclaimer: This article is for informational purposes only and not financial advice. Always research before making investment decisions.